メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
内科学(リウマチ・膠原病)
医学部臨床教室
内科学
概要
フィンガープリント
ネットワーク
プロファイル
(7)
研究成果
(441)
フィンガープリント
内科学(リウマチ・膠原病)が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Immunology and Microbiology
Inflammatory Arthritis
100%
Tocilizumab
38%
Methotrexate
28%
Immunoglobulin G4 Related Disease
28%
Systemic Lupus Erythematosus
21%
Autoantibodies
19%
Immunoglobulin G4
18%
Glucocorticoid
18%
Interleukin 6
17%
Autoimmune Disease
16%
Monospecific Antibody
14%
B Cell
13%
T Cell
12%
Cytokine
12%
Biological Product
11%
Vasculitis
11%
Dermatomyositis
11%
COVID-19
10%
Monocyte
10%
Lymphoproliferative Disorders
10%
Myositis
9%
Vaccination Policy
9%
Follicular B Helper T Cells
9%
Disease-Modifying Antirheumatic Drug
9%
T-Helper Cell
9%
Centromere Antibody
9%
Regulatory T Cell
9%
Anti-Centromere Antibodies
8%
T Helper Cell
8%
Arthritis
8%
Polymyositis
8%
Tumor Necrosis Factor
8%
Drug Megadose
8%
ANCA Associated Vasculitis
8%
Systemic Scleroderma
8%
Adult-Onset Still's Disease
7%
Prednisolone
7%
Infliximab
7%
Connective Tissue
7%
Rheumatic Disease
7%
Immunocompetent Cell
7%
Lupus Erythematosus
7%
Rheumatoid Factor
6%
Abatacept
6%
C-Reactive Protein
6%
Salivary Gland
6%
Gene Expression Profiling
5%
Vaccine Efficacy
5%
Monoclonal Antibody
5%
Adalimumab
5%
Interleukin 4
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Rituximab
5%
CD4
5%
T Cell Subset
5%
Intravenous Immunoglobulin
5%
Medicine and Dentistry
Rheumatoid Arthritis
63%
Tocilizumab
26%
Disease Activity
23%
Disease
22%
Methotrexate
20%
Systemic Lupus Erythematosus
20%
Interstitial Lung Disease
20%
Myositis
16%
Glucocorticoid
16%
Rheumatology
14%
COVID-19
14%
Autoimmune Disease
11%
Biological Product
11%
Vasculitis
10%
Rheumatic Disease
10%
Lymphoproliferative Disease
9%
Autoantibodies
9%
Disease Modifying Antirheumatic Drug
9%
Symptom
9%
Lupus Erythematosus
9%
Systematic Review
9%
Immunosuppressive Treatment
8%
Prednisolone
8%
Janus Kinase Inhibitor
7%
Connective Tissue Disease
7%
Adverse Event
7%
Cohort Analysis
7%
Monotherapy
6%
Drug Therapy
6%
Amino Acid Transfer RNA Ligase
6%
COVID-19 Vaccination
6%
Immunoglobulin G4
6%
Abatacept
6%
Dermatomyositis
6%
Disease Exacerbation
6%
Inflammatory Arthritis
6%
Arthritis
5%
Spontaneous Remission
5%
Nodular Melanoma
5%
Neutrophil Cytoplasmic Antibody
5%
Magnetic Resonance Imaging
5%
Infection
5%
Keyphrases
Rheumatoid Arthritis
51%
Tocilizumab
23%
Japan
20%
Methotrexate
18%
Rheumatology
12%
Remission
12%
Clinical Practice Guidelines
10%
IgG4-related Disease (IgG4-RD)
10%
Rheumatoid Arthritis Patients
10%
Clinical Characteristics
9%
Interleukin-6
9%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
9%
Janus Kinase Inhibitors
8%
Interstitial Lung Disease
7%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
7%
Disease Activity
7%
Risk Factors
7%
Rheumatoid Arthritis Treatment
6%
Autoimmune Disease
6%
Idiopathic Inflammatory Myopathies
6%
Rheumatic Diseases
6%
Monotherapy
5%
Adalimumab
5%
Infliximab
5%
Large Vessel Vasculitis
5%
COVID-19
5%
Lack of Response
5%